Brendan Kelly

Brendan is a Vice President at Lightstone Ventures evaluating opportunities in the biopharmaceutical sector.
Brendan has a background in medicinal chemistry and computational drug discovery research, and life sciences strategy.
Prior to Lightstone, Brendan was Director of New Product Planning at Q32 Bio, where he helped to define value propositions and commercial strategy for the company’s lead assets and discovery platform.
Brendan was previously a life sciences strategy consultant at L.E.K.
Consulting, working on projects across therapeutic areas, modalities and technologies, including pipeline optimization, go-to-market strategies, BD and M&A due diligence.
Brendan’s research at Stanford Computer Science, University of Toronto and Trinity College Dublin focused on computational methods of small molecule drug discovery for oncology and neuroscience targets.
With his background in research and strategy, Brendan is keenly Interested in the intersection of innovative science, company formation and strategy, particularly in the pursuit of new therapeutics for patients in need.